ABEO Abeona Therapeutics Inc.
USHealthcareAs of 2026-07-09 16:00
Why ABEO matters now
Abeona Therapeutics Inc. (ABEO) is a US stock in Healthcare. The latest InvestLog snapshot shows $7.12 with +4.71% on the session and $405.8M in market capitalization; recent performance reads 1-month +12.70% and YTD +9.49%.
The latest financial table shown here is Q1 2026, with revenue of $8.7M, net income of $-17.1M, and EPS of $-0.30. Investors can compare that operating picture with valuation signals such as P/E 3.94 and FCF yield -25.9%.
The latest indexable market news headline is "Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $17.00; recent insider activity includes Vasanthavada Madhav filing J-Other. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
3.94
PEG
0.02
P/B
2.25
P/S
22.62
EV/EBITDA
3.96
DCF Value
$1.01
FCF Yield
-25.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.9%
Operating Margin
-637.9%
Net Margin
454.9%
ROE
41.4%
ROA
33.3%
ROIC
-50.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.7M | $-17.1M | $-0.30 |
| Q4 2025 | $5.4M | $-20.5M | $-0.36 |
| FY 2025 | $5.8M | $71.2M | $1.01 |
| Q3 2025 | $0.00 | $-5.2M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$17.00
Target (Median)
$17.00
Target Range
$17.00 - $17.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.35
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.